![Transparency Market Researchが調査・発行した産業分析レポートです。急性移植片対宿主病（GVHD）治療の世界市場2021年ｰ2031年：薬剤分類別（コルチコステロイド、免疫抑制剤、生物学的療法、キナーゼ阻害剤、モノクローナル抗体、間葉系幹細胞[MSC]、その他）、投与経路別、流通チャネル別 / Acute Graft Versus Host Disease [GvHD] Treatment Market (Drug Class: Corticosteroids, Immunosuppressive Agents, Biological Therapy, Kinase Inhibitors, Monoclonal Antibody, Mesenchymal Stem Cell [MSC], and Others; Route of Administration: Oral, Topical, and Intravenous; and Distributing Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 / MRC2111A048資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-33.gif) | • レポートコード：MRC2111A048 • 出版社/出版日：Transparency Market Research / 2021年7月30日 • レポート形態：英文、PDF、217ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、急性移植片対宿主病（GVHD）治療の世界市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬剤分類別（コルチコステロイド、免疫抑制剤、生物学的療法、キナーゼ阻害剤、モノクローナル抗体）分析、投与経路別分析、流通チャネル別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・急性移植片対宿主病（GVHD）治療の世界市場規模：薬剤分類別（コルチコステロイド、免疫抑制剤、生物学的療法、キナーゼ阻害剤、モノクローナル抗体） ・急性移植片対宿主病（GVHD）治療の世界市場規模：投与経路別 ・急性移植片対宿主病（GVHD）治療の世界市場規模：流通チャネル別 ・急性移植片対宿主病（GVHD）治療の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Acute Graft Versus Host Disease (GvHD) Treatment Market – Scope of Report
TMR’s report on the global acute graft versus host disease (GvHD) treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market over the forecast period from 2021 to 2031. The report provides the overall revenue of the global acute graft versus host disease (GvHD) treatment market for the period from 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global acute graft versus host disease (GvHD) treatment market for the forecast period of 2021–2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global acute graft versus host disease (GvHD) treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomena in the global acute graft versus host disease (GvHD) treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the acute graft versus host disease (GvHD) treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the acute graft versus host disease (GvHD) treatment market.
The report also delves into the competitive landscape of the global acute graft versus host disease (GvHD) treatment market. Key players operating in the global acute graft versus host disease (GvHD) treatment market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the acute graft versus host disease (GvHD) treatment market profiled in this report.
Key Questions Answered in Acute Graft Versus Host Disease (GvHD) Treatment Market Report
How does the development of acute graft versus host disease (GvHD) treatment provide scope of growth in the global acute graft versus host disease (GvHD) treatment market?
How alliances and partnerships between players are widening the scope of new line of therapies for acute graft versus host disease (GvHD) treatment?
What are the revenue share projections of key segments under various criteria in the acute graft versus host disease (GvHD) treatment market during the forecast period?
Which segment is likely to register highest revenue until the end of the forecast period in 2031?
How is the evolving healthcare system in developing countries in Asia Pacific making an impact on the overall acute graft versus host disease (GvHD) treatment market?
Acute Graft Versus Host Disease (GvHD) Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global acute graft versus host disease (GvHD) treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in purview of line of procedure for acute graft versus host disease (GvHD) treatment.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global acute graft versus host disease (GvHD) treatment market in terms of drug class, route of administration, distribution channel, and region. Key segments under each criteria are studied at length and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute graft versus host disease (GvHD) treatment market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Graft Versus Host Disease (GvHD) Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definitions
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
5.2. Key Industry Events
5.3. Pipeline Analysis
5.4. Overview of Companies Offering stem cell treatment and/or Treg cell treatment for Acute Graft Versus Host Disease (GvHD)
5.5. Treatment and Management of Acute Graft Versus Host Disease (aGvHD)
6. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Agents
6.3.3. Biological Therapy
6.3.4. Kinase Inhibitors
6.3.5. Monoclonal Antibody
6.3.6. Mesenchymal Stem Cell (MSC)
6.3.7. Others
6.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class
7. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Topical
7.3.3. Intravenous
7.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration
8. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Region
10. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Corticosteroids
10.2.2. Immunosuppressive Agents
10.2.3. Biological Therapy
10.2.4. Kinase Inhibitor
10.2.5. Monoclonal Antibody
10.2.6. Mesenchymal Stem Cell (MSC)
10.2.7. Others
10.3. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
10.3.1. Oral
10.3.2. Topical
10.3.3. Intravenous
10.4. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Corticosteroids
11.2.2. Immunosuppressive Agents
11.2.3. Biological Therapy
11.2.4. Kinase Inhibitors
11.2.5. Monoclonal Antibody
11.2.6. Mesenchymal Stem Cell (MSC)
11.2.7. Others
11.3. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Oral
11.3.2. Topical
11.3.3. Intravenous
11.4. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Corticosteroids
12.2.2. Immunosuppressive Agents
12.2.3. Biological Therapy
12.2.4. Kinase Inhibitors
12.2.5. Monoclonal Antibody
12.2.6. Mesenchymal Stem Cell (MSC)
12.2.7. Others
12.3. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Topical
12.3.3. Intravenous
12.4. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Corticosteroids
13.2.2. Immunosuppressive Agents
13.2.3. Biological Therapy
13.2.4. Kinase Inhibitors
13.2.5. Monoclonal Antibody
13.2.6. Mesenchymal Stem Cell (MSC)
13.2.7. Others
13.3. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Topical
13.3.3. Intravenous
13.4. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Corticosteroids
14.2.2. Immunosuppressive Agents
14.2.3. Biological Therapy
14.2.4. Kinase Inhibitors
14.2.5. Monoclonal Antibody
14.2.6. Mesenchymal Stem Cell (MSC)
14.2.7. Others
14.3. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Topical
14.3.3. Intravenous
14.4. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Ranking, by Company, 2020
15.3. Company Profiles
15.3.1. Bristol-Myers Squibb
15.3.1.1. Company Description
15.3.1.2. Business Overview
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.3.2. Novartis AG
15.3.2.1. Company Description
15.3.2.2. Business Overview
15.3.2.3. Strategic Overview
15.3.2.4. SWOT Analysis
15.3.3. Mesoblast Ltd
15.3.3.1. Company Description
15.3.3.2. Business Overview
15.3.3.3. Strategic Overview
15.3.3.4. SWOT Analysis
15.3.4. Equillium, Inc.
15.3.4.1. Company Description
15.3.4.2. Strategic Overview
15.3.4.3. SWOT Analysis
15.3.5. Cynata Therapeutics Limited
15.3.5.1. Company Description
15.3.5.2. Business Overview
15.3.5.3. Strategic Overview
15.3.5.4. SWOT Analysis
15.3.6. MaaT Pharma
15.3.6.1. Company Description
15.3.6.2. Strategic Overview
15.3.6.3. SWOT Analysis
15.3.7. Incyte Corporation
15.3.7.1. Company Description
15.3.7.2. Business Overview
15.3.7.3. Strategic Overview
15.3.7.4. SWOT Analysis
15.3.8. Xenikos B.V.
15.3.8.1. Company Description
15.3.8.2. Strategic Overview
15.3.8.3. SWOT Analysis
15.3.9. Merck & Co. (OncoImmune, Inc.)
15.3.9.1. Company Description
15.3.9.2. Business Overview
15.3.9.3. Strategic Overview
15.3.9.4. SWOT Analysis
15.3.10. medac GmbH
15.3.10.1. Company Description
15.3.10.2. SWOT Analysis
15.3.11. CSL Limited
15.3.11.1. Company Description
15.3.11.2. Business Overview
15.3.11.3. SWOT Analysis
Table 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (1/2)
Table 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (2/2)
Table 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 08: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 09: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 12: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 13: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 14: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 15: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 16: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 17: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 19: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 20: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 21: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 22: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 24: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031